Checkpoint Inhibitors Market

Global Checkpoint Inhibitors Market Size (2023 to 2028)

The global checkpoint inhibitors market is estimated to grow at a CAGR of 28.68% during the forecast period. The market's size is predicted to be USD 75.36 billion by 2028 from USD 21.36 billion in 2023.

Global Checkpoint Inhibitors Market Share Insights:

• Based on the drug, the CTLA-4 segment accounted for the major share of the global market in 2022.
• Based on application, the lung cancer segment led the market in 2022.
• Based on region, North America held the largest share of the global market in 2022.

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead to an immune system attack on cancer cells. T-cells launch an attack when it detects infected or Cancerous. The immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells, which lets T-Cells launch an attack on cancer cells.

MARKET DRIVERS:

The rising prevalence of cancer globally primarily drives the growth of the checkpoint inhibitors market. The number of people diagnosing with cancer is growing significantly with each year passing and fuelling the demand for effective cancer treatment options. Checkpoint inhibitors are considered as a promising approach in cancer treatment. Checkpoint inhibitors are used to stimulate the immune system of the patients and to recognize and attack cancer cells. The growing cancer patient population is fuelling the demand for more targeted and effective therapies such as checkpoint inhibitors and this trend is likely to continue in the coming years and drive the market growth.

The growing funding and support from governmental organizations towards the development of new drugs, increasing number of advancements in immunotherapy and checkpoint inhibitor drugs, favorable reimbursement policies for cancer treatments and rising investments in cancer research and development propel the checkpoint inhibitors market growth. The expansion of pharmaceutical companies' pipeline for checkpoint inhibitor drugs, growing awareness about the benefits of immunotherapy in cancer treatment, rapid adoption of combination therapies involving checkpoint inhibitors and increasing number of collaborations and partnerships between pharmaceutical companies for drug development contribute to the checkpoint inhibitors market growth.

The growing number of initiatives and funding from the governments of various countries for cancer treatment and research, the increasing geriatric population which is more susceptible to cancer, the growing incidence of melanoma and non-small cell lung cancer and improved understanding of immune system regulation and tumor microenvironment promote the market growth. Technological advancements in genomics and biomarker discovery, the development of personalized medicine approaches in cancer treatment. The growing availability of diagnostic tools for patient selection, the expansion of healthcare infrastructure and access to advanced cancer treatments, the rising focus on precision medicine and targeted therapies, the supportive regulatory environment for checkpoint inhibitor drugs and patient advocacy and awareness campaigns for immunotherapy in cancer treatment further promote the growth of the checkpoint inhibitors market.

MARKET RESTRAINTS:

The high cost involved in research and development, and the lack of awareness and proper publicity for using these inhibitors, especially in developing regions primarily hamper the growth of the global checkpoint inhibitors market. Immune-related side effects that range from mild to severe with using checkpoint inhibitors, lack of reliable biomarkers, stringent regulatory requirements and approval processes and the competition from other cancer treatment modalities such as targeted therapies and chemotherapy hinders the growth rate of the checkpoint inhibitors market.

REPORT COVERAGE:

This research report on the global checkpoint inhibitors market has been segmented and sub-segmented based on the drug, application, and region.

Checkpoint Inhibitors Market - By Drug:

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4
• Chimeric Antigen Receptor T-cell
• Others

Based on drugs, the CTLA-4 segment is anticipated to account for the major share of the global market during the forecast period. The established role of CTLA-4 in immunotherapy and combination treatment strategies, the efficacy of CTLA-4 in certain cancer types including melanoma and lung cancer and the potential for synergistic effects with PD-1/PD-L1 inhibitors primarily drive the growth of the CTLA-4 segment. The growing understanding of immune checkpoint blockade mechanisms, development of next-generation CTLA-4 inhibitors with improved safety profiles and rising utilization in clinical practice and expanding treatment guidelines further boost the growth rate of the CTLA-4 segment.

The PD-1 inhibitors segment is estimated to hold a considerable share of the global market during the forecast period owing to the rising prevalence of cancer and the need for effective immunotherapy, higher response rates and durable clinical outcomes in various cancer types. Favorable reimbursement policies and increasing adoption by healthcare providers, extensive clinical research and ongoing trials to expand indications, increasing number of collaborations between pharmaceutical companies for drug development and rising awareness among patients and healthcare professionals about PD-1 inhibitors further fuel the growth rate of the PD-1 inhibitors segment.

Checkpoint Inhibitors Market - By Application:

• Lung Cancer
• Renal Cancer
• Blood Cancer
• Bladder Cancer
• Hodgkin Lymphoma
• Melanoma
• Others

Based on application, the lung cancer segment is expected to capture the major share of the global market during the forecast period. The growing incidence and mortality rates of lung cancer globally, rapid adoption of checkpoint inhibitors as a standard treatment option, favorable clinical outcomes and survival benefits in advanced stages and rising emphasis on personalized and targeted therapies for lung cancer drive the growth of the lung cancer segment in the global market. The growing prevalence of non-small cell lung cancer (NSCLC) cases and growing research and clinical trials for novel checkpoint inhibitors in lung cancer further boost the growth rate of the lung cancer segment.

The melanoma segment is estimated to hold a considerable share of the worldwide market during the forecast period owing to the growing incidence of melanoma and increasing awareness among people. High response rates and durable remission achieved with checkpoint inhibitors, an increasing number of advances in immunotherapy and targeted therapies for melanoma, improved survival outcomes and reduced toxicity compared to traditional treatment, rapid adoption of combination therapies for advanced melanoma cases and ongoing research on adjuvant and neoadjuvant checkpoint inhibitor treatments further fuel the growth rate of the melanoma segment.

Checkpoint Inhibitors Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

North America led the checkpoint inhibitors market worldwide in 2022 and the domination of the North American region in the global market is expected in the coming years. The availability of established healthcare infrastructure, high adoption of advanced therapies, extensive research and development activities in immunotherapy, growing prevalence of cancer and increasing demand for effective treatments drive the growth of the North American checkpoint inhibitors market. The strong presence of key market players and collaborations with academic institutions, favorable reimbursement policies for checkpoint inhibitors and rising emphasis on personalized medicine and precision oncology further boost the growth rate of the North American market. The U.S. held the major share of the North American market in 2022, followed by Canada and the same pattern is anticipated to continue during the forecast period.

Europe had a substantial share of the global market in 2022 and is expected to hold a substantial share of the global market during the forecast period. The growing incidence of cancer, increasing awareness about immunotherapies, robust regulatory framework for drug approvals and clinical trials and rapid adoption of novel therapies in major European countries drive the European checkpoint inhibitors market growth. Collaborations between research organizations, academic institutions, and industry players, rising focus on early diagnosis and improved patient outcomes and an increasing number of initiatives from the governments of European countries to enhance cancer treatment and supportive care propel the growth of the European market.

The Asia-Pacific is the fastest-growing regional market for checkpoint inhibitors and is anticipated to hold a considerable share of the global market during the forecast period. The presence of a large patient population and increasing cancer burden, increasing improvements in the healthcare infrastructure, rising healthcare expenditure, growing awareness of immunotherapies and availability of advanced treatments drive the APAC checkpoint inhibitors market growth. The growing research activities and clinical trials in the APAC region, rapid adoption of innovative therapies in key markets such as China, Japan, and India and collaborations between international and local companies for market penetration further boost the growth rate of the APAC market.

The Latin American checkpoint inhibitors market and the MEA checkpoint inhibitors market are also expected to produce a great deal of profit for the key players during the forecast period. Furthermore, due to healthcare development, there will be a rise in demand for the checkpoint inhibitors market in all parts of the world.

KEY MARKET PLAYERS:

Notable companies leading the global checkpoint inhibitors market covered in this report are Merck & Co. Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd, Juno Therapeutics, Novartis International AG, and Kite Pharma.

RECENT MARKET HAPPENINGS:

• In February 2019, Merck & Co., Inc. announced that they had received US FDA approval for the checkpoint inhibitor “Keytruda,” which is used to treat Merkel cell carcinoma.
• For the treatment of non-small cell lung cancer in advanced stages, F. Hoffmann-La Roche Ltd. announced in January 2019 that they received US FDA approval for “Tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin.
• In October 2018, for the treatment of advanced cutaneous squamous cell carcinoma, Regeneron announced that they had received US FDA approval for “Libtayo.”